



INFORMATION CITED BY APPLICANTS THAT MAY BE
MATERIAL TO THE PROSECUTION OF THE SUBJECT APPLICATION

Applicants: P.Y. Lum et al. Attorney Docket No. ROSA122057
Application No.: 10/764,420 Group Art Unit: 1645
Filed: January 23, 2004
Title: METHODS FOR DETERMINING WHETHER AN AGENT
POSSESSES A DEFINED BIOLOGICAL ACTIVITY

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
	U1	6,203,987	B1	03/20/2001	Friend et al.
	U2	6,218,122	B1	04/17/2001	Friend et al.
	U3	6,222,093	B1	04/24/2001	Marton et al.
	U4	2002/0045179	A1	04/18/2002	Snodgrass
	U5	2002/0169562	A1	11/14/2002	Stephanopoulos et al.
	U6	2002/0169730	A1	11/14/2002	Lazaridis

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
	F1	WO 99/37817	A1	07/29/1999	WO		
	F2	WO 01/57776	A2	08/09/2001	WO		
	F3	WO 01/94629	A2	12/13/2001	WO		
	F4	WO 02/37202	A2	05/10/2002	WO		
	F5	WO 02/059560	A2	08/01/2002	WO		

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

OTHER INFORMATION
(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.	
_____	O1	Beer, D.G., et al., "Gene-Expression Profiles Predict Survival of Patients With Lung Adenocarcinoma," <i>Nat. Med.</i> 8(8):816-824, 2002.
_____	O2	Blower, P.E., et al., "Pharmacogenomic Analysis: Correlating Molecular Substructure Classes with Microarray Gene Expression Data," <i>Pharmac. J.</i> 2:259-271, 2002.
_____	O3	Bø, T.H., and I. Jonassen, "New Feature Subset Selection Procedures for Classification of Expression Profiles," <i>Gen. Biol.</i> 3(4):1-11, 2002.
_____	O4	Elbrecht, A., et al., "Compound Characterization Using Gene Microarrays," <i>JALA</i> 6(6):71-75, 2001.
_____	O5	Gerhold, D.L., et al., "Better Therapeutics Through Microarrays," <i>Nat. Genet. Suppl.</i> 32:547-552, 2002.
_____	O6	Hamadeh, H.K., et al., "Gene Expression Analysis Reveals Chemical-Specific Profiles," <i>Toxicol. Sci.</i> 67:219-231, 2002.
_____	O7	Hamadeh, H.K., et al., "Prediction of Compound Signature Using High Density Gene Expression Profiling," <i>Toxicol. Sci.</i> 67:232-240, 2002.
_____	O8	Hughes, T.R., et al., "Expression Profiling Using Microarrays Fabricated by an Ink-Jet Oligonucleotide Synthesizer," <i>Nat. Biotech.</i> 19:342-347, 2001
_____	O9	Levenson, A.S., et al., "Gene Expression Profiles with Activation of the Estrogen Receptor α -Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor," <i>Cancer Res.</i> 62:4419-4426, 2002.
_____	O10	Levenson, A.S., et al., "Molecular Classification of Selective Oestrogen Receptor Modulators on the Basis of Gene Expression Profiles of Breast Cancer Cells Expression Oestrogen Receptor α ," <i>Br. J. Cancer</i> 87:449-456, 2002.
_____	O11	Owa, T., et al., "Array-Based Structure and Gene Expression Relationship Study of Antitumor Sulfonamides Including <i>N</i> -[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and <i>N</i> -(3-Chloro-7-indolyl)-1,4-benzenedisulfonamide," <i>J. Med. Chem.</i> 45:4913-4922, 2002.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- _____ O12 Petricoin III, E.F. et al., "Use of Proteomic Patterns in Serum to Identify Ovarian Cancer," *Lancet* 359:572-577, 2002.
- _____ O13 Rockett, J.C. et al., "DNA Arrays to Monitor Gene Expression in Rat Blood and Uterus Following 17 β -Estradiol Exposure: Biomonitoring Environmental Effects Using Surrogate Tissue," *Toxicol. Sci.* 69:49-59, 2002.
- _____ O14 Stephanopoulos, G., et al., "Mapping Physiological States From Microarray Expression Measurements," *Bioinformatics* 18(8):1054-1063, 2002.
- _____ O15 van 't Veer, L.J., et al., "Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer," *Nature* 415:530-536, 2002.
- _____ O16 Yamazaki, K., et al., "Microarray Analysis of Gene Expression Changes in Mouse Liver Induced by Peroxisome Proliferator-Activated Receptor α Agonists," *Biochem. and Biophys. Res. Comm.* 290:1114-1122, 2002.

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BFM:jlj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100